These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12921114)

  • 1. Cellsorba.
    Shibata H; Kuriyama T; Yamawaki N
    Ther Apher Dial; 2003 Feb; 7(1):44-7. PubMed ID: 12921114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocytapheresis using a leukocyte removal filter.
    Shirokaze J
    Ther Apher; 2002 Aug; 6(4):261-6. PubMed ID: 12164794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter.
    Suemitsu J; Yoshida M; Yamawaki N; Yamashita Y
    Ther Apher; 1998 Feb; 2(1):31-6. PubMed ID: 10227786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease.
    Kawamura A; Saitoh M; Yonekawa M; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J
    Ther Apher; 1999 Nov; 3(4):334-7. PubMed ID: 10608731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytapheresis.
    Takenaka Y
    Artif Organs; 1996 Aug; 20(8):914-6. PubMed ID: 8853806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytapheresis in rheumatoid arthritis.
    Hidaka T; Hashiba Y; Kubo K; Kai Y; Maeda K
    Transfus Apher Sci; 2017 Oct; 56(5):698-702. PubMed ID: 28918917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
    Mitsuyama K; Yamasaki H; Kuwaki K; Takedatsu H; Sata M
    Curr Pharm Des; 2009; 15(18):2110-9. PubMed ID: 19519448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of ulcerative colitis with leukocytapheresis using non-woven polyester filter.
    Sakata H; Kawamura N; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J; Yonekawa M; Saitoh M; Kawamura A
    Ther Apher Dial; 2003 Dec; 7(6):536-9. PubMed ID: 15018240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis.
    Onuma S; Yamaji K; Kempe K; Ogasawara M; Ogawa T; Yang K; Kanai M; Tsuda H; Takasaki Y
    Ther Apher Dial; 2006 Oct; 10(5):404-11. PubMed ID: 17096694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter.
    Hohtatsu K; Yamaji K; Yamada R; Oda K; Kageyama M; Kusaoi M; Onuma S; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Tsuda H; Takasaki Y
    Ther Apher Dial; 2011 Aug; 15(4):355-9. PubMed ID: 21884469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
    Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective leukocyte apheresis for the treatment of inflammatory bowel disease.
    Abreu MT; Plevy S; Sands BE; Weinstein R
    J Clin Gastroenterol; 2007; 41(10):874-88. PubMed ID: 18090155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in the apheresis procedure for the treatment of inflammatory bowel disease.
    Pineda AA
    Inflamm Bowel Dis; 2006 Jan; 12 Suppl 1():S10-4. PubMed ID: 16378005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
    Sawada K
    Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S66-77. PubMed ID: 14530661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Kikuyama M; Tanaka T; Kondo K; Tanaka K; Takai K
    World J Gastroenterol; 2005 May; 11(20):3085-90. PubMed ID: 15918195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of filtration leukocytapheresis on rheumatoid arthritis with vasculitis.
    Hidaka T; Suzuki K
    Ther Apher; 1997 Aug; 1(3):212-4. PubMed ID: 10225740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
    Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T
    J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
    Muratov V; Lundahl J; Mandic-Havelka A; Elvin K; Ost A; Shizume Y; Furuya K; Löfberg R
    J Clin Apher; 2010; 25(5):287-93. PubMed ID: 20806415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
    Mitsuyama K; Sata M
    Cytotherapy; 2009; 11(2):229-37. PubMed ID: 19241197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.